Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Operating Leases (2022 - 2026)

Fulcrum Therapeutics (FULC) has 5 years of Operating Leases data on record, last reported at $3.4 million in Q1 2026.

  • On a quarterly basis, Operating Leases fell 41.94% to $3.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $3.4 million, a 41.94% decrease, with the full-year FY2025 number at $4.0 million, down 37.31% from a year prior.
  • Operating Leases reached $3.4 million in Q1 2026 per FULC's latest filing, down from $4.0 million in the prior quarter.
  • Over the last five years, Operating Leases for FULC hit a ceiling of $12.8 million in Q1 2022 and a floor of $3.4 million in Q1 2026.
  • A 5-year average of $8.1 million and a median of $8.1 million in 2024 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: decreased 20.05% in 2024, then tumbled 41.94% in 2026.
  • Tracing FULC's Operating Leases over 5 years: stood at $10.8 million in 2022, then dropped by 20.26% to $8.6 million in 2023, then dropped by 25.33% to $6.4 million in 2024, then plummeted by 37.31% to $4.0 million in 2025, then fell by 15.67% to $3.4 million in 2026.
  • Business Quant data shows Operating Leases for FULC at $3.4 million in Q1 2026, $4.0 million in Q4 2025, and $4.7 million in Q3 2025.